WednesdayNov 18, 2026 1:00 pm

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Advances Peptide Innovation and GLP-1 Companion Strategy

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is positioning to capitalize on potential changes in U.S. peptide regulations that could expand access through specialty pharmacies and telehealth platforms. As the FDA considers allowing additional peptides for pharmacy compounding, the company plans to differentiate itself by developing proprietary peptide formulations and delivery technologies designed to improve stability, absorption, administration and performance. Adaptogenics has also acquired nutritional research assets from Berkwood Research to support a GLP-1 companion initiative focused on preserving muscle mass, strength and metabolic health during medically induced weight loss. Recent leadership…

Continue Reading

WednesdayNov 18, 2026 10:40 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Schedules Third Quarter 2026 Financial Results and Conference Call for Nov. 25

Nanox (NASDAQ: NNOX) announced plans to showcase its medical imaging technologies at the Radiological Society of North America ("RSNA") 2026 Annual Meeting, scheduled for Nov. 29 through Dec. 2 in Chicago. At booth #1759 (South Hall Level 3), the company will demonstrate Nanox.ARC X, its U.S. Food and Drug Administration ("FDA")-cleared multi-source digital tomosynthesis system recognized among TIME's Best Inventions of 2026, alongside Nanox.AI, which uses FDA-cleared artificial intelligence ("AI") algorithms to analyze routine computed tomography ("CT") scans for early signs of chronic conditions. Nanox will also highlight its USARAD teleradiology services and Nanox Health IT solutions. The company plans…

Continue Reading

WednesdayNov 18, 2026 9:40 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended Sept. 30, 2026, highlighting progress across its artificial intelligence ("AI")-driven oncology pipeline and approximately $4 million in gross proceeds from financing completed at quarter end. In November, the company engaged its first clinical site to begin initial enrollment in a Phase 1b/2 trial targeting relapsed or refractory triple-negative breast cancer ("TNBC"). Lantern also received regulatory and institutional review board approvals in Taiwan in September to initiate Part 2 of its Phase 2 HARMONIC(TM) trial evaluating LP-300 in never-smokers with L858R-mutated non-small cell lung cancer. The…

Continue Reading

TuesdayNov 17, 2026 10:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives USPTO Notice of Allowance for Abuse-Deterrent Fentanyl Patch Brand Names

Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026, from the United States Patent and Trademark Office ("USPTO") for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company intends to pursue full trademark registration in the United States and internationally and is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and other regulatory authorities for preapproval review. Nutriband said its naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names. The company's lead…

Continue Reading

MondayNov 16, 2026 11:20 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Reports Up to 83% Accuracy in AI Intoxication Detection Testing, Announces $350,000 Private Placement

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced that its artificial intelligence ("AI")-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests. MindBio plans to conduct additional human testing over the next two to three weeks before launching its first commercial…

Continue Reading

MondayNov 16, 2026 10:00 am

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) reported financial results and business updates for its fiscal second quarter ended Sept. 30, 2026, highlighting continued development of its novel serotonergic agonist ("NSA") pipeline. The company ended the quarter with $171.1 million in cash and reported a net loss of $103.1 million, compared with $33.7 million in the prior-year period. Operating expenses excluding share-based compensation increased to $39.6 million from $28.5 million, primarily reflecting continued advancement of its Phase 3 clinical program. Cash used in operating activities…

Continue Reading

FridayNov 13, 2026 11:00 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, highlighting improved liquidity, reduced operating expenses and progress in its clinical development program. Cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders' equity increased 91% to $9.77 million, while working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from…

Continue Reading

ThursdayNov 12, 2026 1:37 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a vertically integrated healthcare platform while expanding its presence across real estate, asset management and consumer products. Its healthcare operations combine compounding pharmacies, telemedicine, clinical support and direct-to-patient fulfillment, supported by internal technology, proprietary physician networks and owned real estate. The company’s acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients and FDA-approved prescription products, further strengthens supply chain control and provides its pharmacies with access to competitively priced ingredients. By bringing more operational functions in-house and leveraging the capabilities of its subsidiaries, Earth…

Continue Reading

ThursdayNov 12, 2026 1:08 pm

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and…

Continue Reading

WednesdayNov 11, 2026 9:10 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9. Shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over implementing the…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000